Logistic regression was then used to assess the relationship of demographic and professional factors in several ways, eg: (i) recognition of suspected ADRs in the past 4 weeks; and for those in post for at least 1 year and (ii) having reported at least one suspected ADR in the past 12 months.
Poor recognition could account for the low estimate of the incidence of ADR-related ED visits as noted in a German study that more than half of the pre-existing ADRs were not recognized by either the admitting or the attending physician.[ 5] Finally, we note that there is likely to be facility-level variability in identification and coding of ADRs in the CIHI databases used in this analysis.
Despite recognition of the occurrence and burden of ADRs and the need to report them, several studies show that there is widespread under-reporting of ADRs to spontaneous reporting systems, including serious or severe ADRs [ 6– 9].
To assess extent and determinants of past-month recognition of suspected adverse drug reactions (ADR) and past-year ADR reporting among healthcare professionals (HCPs) in Uganda.
Information obtained from clinical ADRs, from recognition of specific phenotypes of animal models and from hereditary diseases provides increasing regulatory confidence in the target-based approach to ADR prediction and mitigation.
The importance of this discipline has been achieved by increasing its translational value, based on the recognition of biological target drug molecule adverse drug reaction (ADR) associations and integration of secondary pharmacology data with pharmacokinetic parameters.
We then demonstrated that blockade of β1-ADR affects the recognition of social cues without affecting general olfactory abilities and discrimination (Fig. 2C and D).
A questionnaire was designed addressing; awareness of ADRs, knowledge of pharmacovigilance system, availability of ADRs reporting system, patient counseling about ADRs and documentation of ADRs.
Our method outperformed random for all ADRs, whereas all other methods were no better than random for a proportion of ADRs (DT 7.9%, SVM 41.9%, LR 27.5%).
Pharmacovigilance systems are aimed at early detection of ADRs.
